Breast Augmentation in India
Get Breast Augmentation at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Breast Augmentation in UAE
Breast Augmentation at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Breast augmentation is a surgical procedure that uses silicone gel or saline implants—or autologous fat transfer—to enhance breast volume, improve symmetry, and restore projection lost to pregnancy, weight loss, or congenital asymmetry, achieving patient satisfaction rates consistently above 95% in high-volume centres. India and the UAE have emerged as premier destinations for this procedure, offering board-certified plastic surgeons trained at institutions such as AIIMS, Johns Hopkins, and Cleveland Clinic, paired with JCI- and NABH/DHA-accredited facilities that meet or exceed Western clinical standards. GAF Healthcare coordinates every step of the patient journey—from pre-operative imaging and surgical planning to post-operative follow-up and fit-to-fly clearance—ensuring international patients receive world-class outcomes at a fraction of the cost they would incur at home.
Hospital Stay: 1–2 days • Total Stay in Country (Fit-to-Fly): 2–3 weeks • Success Rate: 95–98%
What Is It?
Breast augmentation (augmentation mammaplasty) is one of the most performed elective plastic surgery procedures globally, with over 1.8 million procedures carried out worldwide annually according to ISAPS data. The surgery addresses hypomastia (insufficient breast volume), post-lactational involution, developmental asymmetry, and Poland syndrome-related chest wall deformity. Beyond aesthetics, the physiological impact extends to postural balance—significant volume discrepancies can cause compensatory cervical and thoracic strain—and to psychological well-being, where validated tools such as the BREAST-Q patient-reported outcome measure consistently demonstrate improvements in self-image, sexual well-being, and psychosocial function following successful augmentation.
The contemporary standard of care centres on a thorough pre-operative assessment including high-resolution breast ultrasound or MRI (mandatory in patients over 40 or with dense breast tissue on BIRADS classification), three-dimensional volumetric imaging using systems such as the Vectra XT or Crisalix platform for implant simulation, and tissue-based planning (TBP) using the High Five assessment developed by Tebbetts and Adams. Implant selection is guided by base width, skin stretch, and soft tissue coverage—parameters that determine whether a patient is better served by a moderate-profile, high-profile, or ultra-high-profile device, and whether a smooth or textured shell is appropriate. All implants used in GAF Healthcare partner hospitals are CE-marked and FDA-cleared devices from manufacturers including Allergan Natrelle, Mentor MemoryGel, Motiva Ergonomix, and Sientra.
Antibiotic prophylaxis protocols at partner centres follow the 14-point plan published by Adams and Bengtson, which has demonstrated a greater than 50% reduction in capsular contracture rates compared to older regimens. Postoperative monitoring includes structured follow-up at 1 week, 6 weeks, 3 months, and 1 year, with implant integrity surveillance via ultrasound or MRI at 3–5 years post-implantation per FDA guidance. This rigorous standard-of-care framework ensures that patients treated through GAF Healthcare receive outcomes that are reproducible, evidence-based, and durable over the long term.
Candidates
• Women aged 18 years or older (minimum 22 years for silicone gel implants per FDA labelling, though international guidelines may differ slightly)
• Patients with hypomastia, breast asymmetry of ≥1 cup-size differential, post-partum breast volume loss, or congenital chest wall deformities such as Poland syndrome or tuberous breast deformity
• Patients with a stable body weight (BMI ideally 18.5–30 kg/m²) for at least 6 months prior to surgery
• Non-smokers, or patients who have ceased smoking for a minimum of 6 weeks pre-operatively (nicotine impairs wound healing and increases capsular contracture risk)
• Patients with adequate soft tissue coverage: a pinch test of ≥2 cm is preferred for subglandular placement; ≤2 cm typically indicates the dual-plane or submuscular approach
• Patients with realistic expectations documented through pre-operative psychological screening and structured consultation using BREAST-Q baseline scoring
Required Diagnostics:
• Bilateral breast ultrasound (standard); MRI for patients over 40, those with dense tissue (BIRADS C or D), or personal/family history of breast disease
• Baseline mammography in patients ≥40 years or as clinically indicated
• 3D volumetric imaging (Vectra XT / Crisalix simulation) for implant size and profile planning
• Routine pre-operative bloods: CBC, coagulation profile (PT/INR/aPTT), metabolic panel, HbA1c if diabetic
• ECG and anaesthetic fitness assessment for patients over 45 or with cardiopulmonary comorbidities
• Pregnancy test (urine or serum beta-hCG) on day of surgery
Contraindications:
• Active breast infection, mastitis, or undiagnosed breast mass pending biopsy
• Current pregnancy or breastfeeding
• Active autoimmune connective tissue disorders (e.g., systemic lupus erythematosus, systemic sclerosis) — relative contraindication requiring multidisciplinary review
• Uncontrolled diabetes (HbA1c >8%) or poorly optimised cardiovascular disease
• Active malignancy or history of breast cancer without oncology clearance
• Severe coagulopathy or anticoagulation therapy that cannot be safely bridged
• Body dysmorphic disorder (BDD) — identified through pre-operative psychological screening using the BDD-YBOCS or BDDQ instrument; surgery is contraindicated until psychiatric clearance is obtained
Procedure
Breast augmentation encompasses several distinct surgical strategies, each selected based on patient anatomy, tissue characteristics, implant type, and aesthetic goals.
IMPLANT-BASED AUGMENTATION (PRIMARY TECHNIQUE):
1. Incision Approaches:
• Inframammary fold (IMF) incision: The most commonly used approach globally; provides direct, precise pocket dissection and is preferred for anatomical/shaped implants. Scar is concealed within the natural breast fold.
• Periareolar incision: Semi-circular incision along the inferior areolar border; suitable for simultaneous mastopexy or correction of tuberous breast. Carries slightly higher risk of sensory nerve disruption and biofilm contamination.
• Transaxillary incision: Scar placed in the axillary crease; no breast scar. Performed endoscopically using a lighted retractor system. Technically demanding; limited pocket control for large implants.
• Transumbilical breast augmentation (TUBA): Used exclusively with saline implants; rarely performed in modern practice due to limited implant selection and pocket control.
2. Implant Pocket Planes:
• Subglandular (above pectoralis major): Direct, shorter recovery; suitable for patients with pinch test >2 cm. Higher capsular contracture rate historically.
• Submuscular / Dual-plane (below or partially below pectoralis major): The Tebbetts Dual-Plane classification (Types I, II, III) allows customisation of muscle release to optimise lower pole fill and reduce animation deformity. Currently the most widely utilised plane in high-volume centres.
• Subfascial placement: Implant placed beneath the pectoral fascia but above the muscle; emerging technique offering intermediate benefits of subglandular and submuscular planes with reduced animation.
3. Implant Types:
• Cohesive silicone gel (form-stable / 'gummy bear'): Allergan Inspira, Mentor MemoryGel Boost, Motiva Ergonomix. Ergonomix implants feature a BluSeal barrier layer detectable on ultrasound and a progressive gel that adapts to position changes, mimicking natural breast movement.
• Saline implants: Filled intraoperatively to precise volume; deflation is immediately apparent, enabling easy detection. Suitable for patients with adequate soft tissue coverage.
• Structured saline (IDEAL IMPLANT): Internal baffle structure reduces rippling while avoiding silicone gel.
• Round vs. anatomical (teardrop) shaped: Anatomical implants require textured shells to resist rotation; associated with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) risk with certain macro-textured devices (Biocell surface). All GAF Healthcare partner hospitals use only smooth or micro-textured devices from manufacturers with verified safety data.
FAT TRANSFER BREAST AUGMENTATION (AUTOLOGOUS TECHNIQUE):
• Suitable for patients seeking modest enhancement (approximately 0.5–1.5 cup sizes) with no implant. Involves high-definition liposuction (VASER or laser-assisted) from donor sites (abdomen, flanks, thighs), followed by Puregraft or Coleman technique centrifugation and structured fat injection into the breast parenchyma and subcutaneous plane.
• Grafted fat viability is approximately 60–80% at 1 year; multiple sessions may be required for optimal volume.
• Pre-expansion using the BRAVA external tissue expander system can increase recipient site capacity and improve fat take rates.
• Contraindicated in patients with insufficient donor fat reserves (BMI <20) or active breast disease.
COMBINED / HYBRID AUGMENTATION:
• Implant plus fat grafting in a single operative session; addresses both volume and contour irregularities, particularly upper pole hollowing or rippling in thin patients.
ANESTHESIA:
• Performed under general anaesthesia (TIVA — Total Intravenous Anaesthesia using propofol and remifentanil) in accredited operating theatres with full anaesthetic monitoring including BIS (Bispectral Index) monitoring for depth of anaesthesia. ERAS (Enhanced Recovery After Surgery) protocols incorporating pre-emptive multimodal analgesia (paracetamol, NSAIDs, dexamethasone, local anaesthetic field block with liposomal bupivacaine/Exparel) are standard at GAF Healthcare partner hospitals, significantly reducing opioid requirements and accelerating recovery.
Cost of Breast Augmentation: India vs. UAE
The cost of breast augmentation varies significantly depending on the destination, implant brand and type, surgical complexity, and the accreditation tier of the hospital. India offers exceptional value with costs typically 55–65% lower than equivalent procedures in the UAE or Western countries, while the UAE provides a luxury-tier experience with premium facilities in Dubai's Healthcare City and Abu Dhabi, appealing to patients from GCC nations, Europe, and Africa who prioritise proximity and comfort. Both destinations offer internationally accredited centres with surgeons holding fellowship training from ISAPS, ASPS, or EBOPRAS. The estimates below reflect all-inclusive surgical packages at JCI-accredited partner hospitals and cover standard silicone gel implant augmentation; fat transfer procedures and combined augmentation-mastopexy carry higher costs.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,800 – $5,500 | ~55% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $6,500 – $12,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-OPERATIVE PLANNING (4–8 weeks before travel):
• GAF Healthcare assigns a dedicated Patient Coordinator who collects medical history, current medications, and previous imaging reports.
• Virtual consultation with the operating plastic surgeon (video call) for anatomical assessment, goal alignment, and implant simulation using digital imaging.
• Pre-operative investigations (bloods, ECG, breast ultrasound/MRI) arranged either at the patient's home country or upon arrival; reports reviewed by the surgical team.
• e-Medical visa application assistance initiated for India-bound patients (typically approved within 3–5 business days); UAE entry visa or visa-on-arrival guidance provided for UAE-bound patients.
• Anaesthetic fitness questionnaire completed; any concurrent medications reviewed (aspirin, NSAIDs, oral contraceptives, anticoagulants adjusted per protocol).
PHASE 2 — ARRIVAL & IMMEDIATE PRE-OPERATIVE (Day 0–1):
• Airport pick-up in a dedicated GAF Healthcare vehicle; transfer to partner hospital or pre-arranged accommodation.
• In-person consultation and physical examination by operating surgeon; final implant size confirmed using sizers.
• Pre-operative marking in the upright position; 3D scan completed if not done remotely.
• Consent process, anaesthetic review, and pre-operative instructions (nil by mouth from midnight).
PHASE 3 — SURGERY DAY (Day 1):
• Procedure duration: 1–2 hours for standard implant augmentation; 3–4 hours for fat transfer or combined procedures.
• Adams 14-point antibiotic prophylaxis protocol initiated (IV cefazolin induction, triple antibiotic irrigation of implant pocket, implant dipped in triple-antibiotic solution, minimal-touch technique, funnel insertion device used to eliminate skin contact).
• Patient transferred to recovery room; drain assessment (drains rarely required for standard augmentation).
• Surgical bra applied; initial post-operative analgesia administered per ERAS protocol.
PHASE 4 — HOSPITAL STAY & EARLY RECOVERY (Day 1–2):
• Overnight observation standard (1 night in hospital); 2 nights if combined with mastopexy or fat transfer.
• Pain assessed using Numeric Rating Scale (NRS); managed with scheduled paracetamol, ibuprofen, and low-dose opioids only as rescue analgesia.
• Wound check and dressing change before discharge; post-operative instructions provided in the patient's language.
• Discharge to hotel or patient accommodation managed by GAF Healthcare.
PHASE 5 — IN-COUNTRY RECOVERY (Days 2–21):
• Day 3–5: Suture/dressing review at clinic. Light upper body movement encouraged; no overhead lifting.
• Day 7: Steri-strips or surgical tape assessed; dissolvable sutures reviewed. Most patients are comfortable for light walking and tourism activities.
• Day 10–14: Surgeon clearance appointment; breast displacement exercises (implant mobilisation) commenced if instructed, to reduce capsular contracture risk in dual-plane cases.
• Week 2–3: FIT-TO-FLY ASSESSMENT — The operating surgeon evaluates wound integrity, absence of haematoma/seroma, blood pressure stability, and DVT risk before issuing fit-to-fly clearance. Most patients are cleared for long-haul flight at 2–3 weeks post-operatively. Compression stockings and low-molecular-weight heparin (LMWH) prophylaxis are prescribed for flights exceeding 4 hours.
PHASE 6 — LONG-TERM RECOVERY MILESTONES:
• 6 weeks: Return to full upper body exercise, underwire bras permitted, return to work (desk job typically at 2 weeks; physical work at 6 weeks).
• 3 months: Final implant position settled; surgical bra no longer mandatory; BREAST-Q follow-up questionnaire completed.
• 6–12 months: Final aesthetic assessment; scar maturation assessed; follow-up ultrasound if clinically indicated.
• 3–5 years: First MRI or ultrasound implant integrity screen per FDA guidance.
Risks & Considerations
Breast augmentation, while one of the most refined elective surgical procedures, carries real and procedure-specific risks that every patient must understand before consent. Capsular contracture (abnormal scar tissue formation around the implant) is the most common long-term complication, graded I–IV on the Baker Classification; rates range from 1–3% at 10 years with modern smooth implants and antibiotic protocols to 10–15% historically with older devices. BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) is a rare but serious T-cell lymphoma linked primarily to macro-textured implants; estimated incidence is 1 in 2,000–86,000 with textured devices; risk is near-negligible with smooth implants used at GAF Healthcare partner centres. All patients should be counselled per the FDA Black Box Warning issued in 2021 regarding Breast Implant Illness (BII), a constellation of systemic symptoms (fatigue, cognitive fog, arthralgia) reported by a subset of patients and under active investigation. Implant rupture rates for modern cohesive silicone gel devices are approximately 1% per year; silent rupture is detected only on MRI, reinforcing the importance of surveillance imaging. Other documented risks include haematoma (1–2%), seroma, infection (0.5–1.5%), altered nipple-areola sensation (transient in up to 15%, permanent in <2%), implant malposition, animation deformity (visible implant movement with pectoral contraction, particularly in submuscular placement), rippling, and asymmetry requiring revision. Anaesthetic risks are managed through pre-operative ASA Physical Status Classification, BIS-monitored TIVA, and PONV (post-operative nausea and vomiting) prophylaxis with ondansetron and dexamethasone. DVT/PE risk for long-haul travel post-operatively is mitigated with LMWH prophylaxis and compression stockings prescribed before the return flight, combined with adequate hydration and in-flight mobility exercises.
Top Hospitals for Breast Augmentation
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
All India Institute of Medical Sciences (AIIMS)
New Delhi, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Christian Medical College (CMC)
Vellore, India
Manipal Hospitals Dwarka
New Delhi, India
Top Doctors for Breast Augmentation
Internationally trained specialists in Cosmetic Surgery. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ananya Deori
MCh, MS, MBBS
Breast Surgeon
Medanta - The Medicity, Delhi NCR, India
9+ Yearsof experience
Dr. Ananya Deori is an Associate Consultant in Breast Surgery at Medanta - The Medicity in Delhi NCR, bringing over 9 years of specialized surgical experience to the field of breast oncology. She holds an MCh degree in Breast and Endocrine Surgery from AIIMS Rishikesh, one of India's premier medical institutions, complemented by postgraduate qualifications in General Surgery. Her training in one of the country's most rigorous breast surgery programs has… Read more
Dr. Swathi Prakash
MCh, MS, MBBS
Breast Surgical Oncologist
Rela Hospital, Chennai, India
15+ Yearsof experience
Dr. Swathi Prakash is a Consultant in Breast Surgery and Surgical Oncology at Rela Hospital in Chennai, with over 15 years of clinical experience. She holds an MCh in Breast & Endocrine Surgery from All India Institute of Medical Sciences (AIIMS), New Delhi, and was the first in Tamil Nadu to achieve this distinction in breast surgery. Her comprehensive training encompasses both benign and malignant breast disease management, underpinned by rigorous… Read more
Dr. Mansi Chowhan
MBBS, MS (General Surgery) – Gold Medalist, MCh Breast Oncoplasty, Fellowship in Breast Surgery, Global Fellowship IFHNOS, FIAGES – Fellow of Indian Association of Gastro Endoscopic Surgeons, Observership – Breast Unit
Oncoplastic Breast Surgeon
Fortis Hospital Manesar, Gurugram, India
14+ Yearsof experience
Dr. Mansi Chowhan is an expert Oncoplastic Breast Surgeon with more than 14 years of experience and a gold medal during her surgical post-graduation. She is well-trained from world-renowned surgeons and cancer institutions including the Paris Breast Centre, Memorial Sloan Kettering Cancer Centre (New York), University of East Anglia (UK), and Tata Memorial Hospital, Mumbai. Her role as a Consultant in Surgical Oncology has been marked by dedication to… Read more
Dr. Aditi Chaturvedi
MBBS, MS, MCh
Breast and Oncoplastic Surgeon
Apollo Athenaa Women's Cancer Centre, New Delhi, India
13+ Yearsof experience
Dr. Aditi Chaturvedi is a Senior Consultant Breast and Oncoplastic Surgeon at Apollo Athenaa Women's Cancer Centre in New Delhi, bringing over 13 years of dedicated expertise in breast oncology and surgical reconstruction. A Fellow of the UICC at Memorial Sloan Kettering Cancer Center in New York, she holds postgraduate qualifications including MS in General Surgery and MCh in Surgical Oncology, positioning her at the forefront of breast cancer care in… Read more
Frequently Asked Questions — Breast Augmentation
In India, breast augmentation at a JCI- or NABH-accredited hospital through GAF Healthcare typically costs between USD 2,800 and USD 5,500 for a standard silicone gel implant procedure, inclusive of surgeon fees, operating theatre charges, anaesthesia, a 1–2 night hospital stay, FDA/CE-cleared implants (Allergan, Mentor, or Motiva), and standard post-operative medications. In the UAE (Dubai or Abu Dhabi), the equivalent procedure at a JCI- or DHA-licensed facility ranges from USD 6,500 to USD 12,000, reflecting the higher cost of premium facilities, luxury recovery environments, and the elevated cost of healthcare delivery in the Gulf. Combined procedures such as augmentation with mastopexy, or fat transfer augmentation, carry higher costs in both destinations. These figures represent a saving of 60–80% compared to equivalent procedures in the United Kingdom, United States, or Australia. GAF Healthcare provides a fully itemised cost breakdown before any financial commitment is made.
GAF Healthcare recommends a minimum in-country stay of 14–21 days (2–3 weeks) following breast augmentation before undertaking an international flight. Fit-to-fly clearance is issued by the operating plastic surgeon following a formal clinical assessment that confirms wound integrity, absence of haematoma or seroma, stable cardiovascular observations, and absence of early capsular contracture or infection. Most patients are comfortable for light activities from Day 7, but flight clearance is typically granted between Day 14 and Day 21 depending on surgical complexity (standard augmentation vs. combined augmentation-mastopexy or fat transfer). Patients cleared for long-haul travel (flights exceeding 4 hours) are routinely prescribed low-molecular-weight heparin (LMWH) injections and graduated compression stockings to mitigate DVT risk associated with prolonged immobility at altitude. Adequate hydration and regular in-seat leg exercises are also advised. Patients from the GCC region traveling to Dubai or Abu Dhabi (short return journeys under 4 hours) may be cleared to return slightly earlier, at 10–14 days, at the surgeon's discretion.
Breast augmentation carried out at GAF Healthcare's JCI-accredited partner hospitals in India and the UAE achieves patient satisfaction rates of 95–98% as measured by the validated BREAST-Q patient-reported outcome instrument at 3- and 12-month follow-up. Surgical success—defined as achieving the planned aesthetic outcome without the need for unplanned revision within 12 months—is reported at greater than 97% at high-volume centres with board-certified ISAPS/ASPS-trained surgeons. Long-term implant integrity at 10 years is approximately 90–95% for modern cohesive silicone gel devices (Allergan Natrelle, Mentor MemoryGel, Motiva Ergonomix) under FDA post-market surveillance data. Capsular contracture rates (Baker Grade III–IV, requiring intervention) are below 3% at high-volume centres employing the Adams 14-point antibiotic prophylaxis protocol and smooth or micro-textured implants. These outcomes are contingent on rigorous patient selection, experienced surgical technique, and adherence to the structured post-operative follow-up programme that GAF Healthcare coordinates for all international patients.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides an end-to-end non-medical support infrastructure designed to eliminate the administrative and logistical burden for international patients traveling to India or the UAE.
VISA ASSISTANCE:
• India: GAF Healthcare facilitates the e-Medical Visa application, which permits a stay of up to 60 days (triple entry) and is approved by the Indian Bureau of Immigration within 3–5 business days. Patients must hold a valid passport and provide a letter of medical appointment from the partner hospital — GAF Healthcare prepares this documentation on behalf of the patient. Attendant (companion) e-Medical Visas are applied simultaneously.
• UAE: Citizens of over 90 countries receive visa-on-arrival or pre-approved visit visas for the UAE. GAF Healthcare advises on the patient's specific nationality requirements and, where pre-approval is needed, liaises with UAE immigration through the partner hospital's international patient services department.
AIRPORT & GROUND TRANSFERS:
• Private air-conditioned vehicle transfers are arranged for all arrival, hospital, and departure journeys. Vehicles are accessible for patients with mobility restrictions and are equipped with a medical attendant for post-operative transfers.
DEDICATED PATIENT COORDINATOR:
• Each patient is assigned a named bilingual Patient Coordinator who is reachable 24/7 via WhatsApp, phone, and email throughout the entire journey — from initial enquiry through to post-operative follow-up video calls with the surgical team.
TRANSLATION & INTERPRETATION:
• Professional medical interpreters are available for Arabic, Russian, French, Swahili, and other languages during in-person consultations, consent discussions, and hospital admission. All consent documents and post-operative instruction sheets are provided in the patient's preferred language.
ACCOMMODATION:
• GAF Healthcare has negotiated preferred rates at partner hotels and serviced apartments within 10–15 minutes of all partner hospitals. Attendant accommodation is arranged concurrently and includes meals, housekeeping, and reliable Wi-Fi. For patients requiring more intensive post-operative monitoring, medical recovery suites within or adjacent to the hospital are available.
INSURANCE & MEDICAL RECORDS:
• GAF Healthcare assists patients in obtaining international medical travel insurance that covers post-operative complications. Complete medical records, operative notes, implant device card (serial number, model, lot number), and surgeon contact details are provided in a patient dossier for presentation to the patient's home country physician at follow-up.
Patients Also Explore
Other treatments commonly sought by patients considering Breast Augmentation.
LASIK Eye Surgery
Ophthalmology
Cataract Surgery
Ophthalmology
Cochlear Implant
ENT
Hyperthyroidism Treatment
ENT